Coronary Vasoconstrictor Effects of Atriopeptin II
- 1 November 1985
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 230 (4725) , 558-561
- https://doi.org/10.1126/science.2931801
Abstract
Atrial natriuretic peptides lower arterial pressure, cardiac filling pressure, and cardiac output. In isolated, Langendorff-perfused guinea pig hearts, atriopeptin II, the 23-amino acid atrial natriuretic peptide, is also a potent coronary vasoconstrictor. The median effective dose for atriopeptin II in guinea pig hearts is 26 nanomoles, the threshold constrictor dose is 5 nanomoles, and flow nearly ceases at a dose of 100 nanomoles in perfused hearts at constant pressure. Similar concentrations of atriopeptin II also cause coronary vasoconstriction in rat and dog heart preparations. The disulfide bridge is necessary for vasoconstrictor activity; reduction of this bridge abolishes the activity, as it does the other biological activities of atrial natriuretic peptides.This publication has 11 references indexed in Scilit:
- Effect of pulmonary and renal circulations on activity of atrial natriuretic factorAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1985
- Stimulation of cyclic GMP formation in smooth muscle cells by atriopeptin II.Life Sciences, 1985
- The Heart and the Atrial Natriuretic Factor*Endocrine Reviews, 1985
- Comparative vascular pharmacology of the atriopeptins.Circulation Research, 1985
- Immunocytochemical localization of atrial natriuretic factor in the heart and salivary glandsHistochemistry and Cell Biology, 1984
- Bioactive Cardiac Substances: Potent Vasorelaxant Activity in Mammalian AtriaScience, 1983
- Heart Atria Granularity Effects of Changes in Water-Electrolyte BalanceExperimental Biology and Medicine, 1979
- SPECIFIC GRANULES IN ATRIAL MUSCLE CELLSThe Journal of cell biology, 1964
- Solid-Phase Peptide Synthesis. III. An Improved Synthesis of Bradykinin*Biochemistry, 1964